NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Not Allowed) | RFA CA 20 014

Opportunity Information: Apply for RFA CA 20 014

The NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00; Independent Clinical Trial Not Allowed) is an NIH/National Cancer Institute grant mechanism meant to help exceptional postdoctoral researchers move quickly from mentored training into fully independent faculty careers. The central goal is workforce development for cancer research: NCI uses this program to build and sustain a strong pipeline of new investigators who can compete successfully for future independent research funding and establish long-term research programs. The opportunity is aimed at postdoctoral fellows who already have strong research preparation through a research doctorate and/or clinical doctorate and who do not need a prolonged additional mentored training period beyond their doctoral degree.

Structurally, this is a two-phase "bridge" award. The first phase (the K99 mentored phase) supports the applicant while they remain in a postdoctoral position under mentorship, focusing on completing key training and research milestones that position them to be hired into an independent role. The second phase (the R00 independent phase) provides research support after the awardee secures a tenure-track or equivalent independent faculty position. In practice, the design is meant to reduce the career gap that often occurs between postdoctoral training and the first independent grant by providing continuity of support while the scientist transitions institutions and professional status. The intended outcome is not just publications during a postdoc, but a timely move into independence with a clear, fundable research direction and the early evidence needed to launch a competitive laboratory or research program.

NCI notes particular encouragement for applicants working in data science and cancer control science. While the announcement does not limit applications to these areas, it signals priority interest in research that can strengthen cancer prevention, population science, healthcare delivery, survivorship, implementation, and analytic or computational approaches that improve how cancer-related data are generated, integrated, modeled, or used to guide decisions. The broader fit is cancer-relevant research consistent with NCI priorities, with an emphasis on projects that can realistically mature into an independent program by the time the investigator reaches the R00 stage.

A key restriction in this specific FOA is the clinical trial leadership limitation. Applicants are not allowed to propose leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial as the main investigator under this announcement. However, the FOA does allow the applicant to gain experience in a clinical trial that is led by their mentor or co-mentor, which can be useful for postdocs in clinically adjacent areas who want exposure to trial operations without being the trial lead. If an applicant intends to be the lead investigator for a clinical trial or ancillary trial within the K99/R00 project, they are directed to apply to the companion FOA (RFA-CA-20-015), which is structured for that purpose.

Eligibility is broad at the organizational level, spanning many U.S. institution types and sectors that commonly host NIH-funded research and career development activities. Eligible applicant organizations include public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (other than small businesses) and small businesses, as well as various governmental entities (state, county, city/township, special districts), independent school districts, public housing/Indian housing authorities, and federally recognized Native American tribal governments and other eligible tribal organizations. The announcement also explicitly highlights categories such as Historically Black Colleges and Universities, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions, along with faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.

Foreign eligibility is more limited and nuanced. Non-U.S. institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are not eligible to apply as applicant components. At the same time, the FOA allows "foreign components" as defined by NIH policy, meaning certain collaborations or activities that meet NIH's foreign component definition can be included when appropriately justified and compliant with NIH rules. In other words, the award is fundamentally anchored in an eligible U.S.-based applicant organization, but may include approved international elements under NIH policy where relevant.

Administratively, the opportunity is a discretionary grant from NIH under CFDA 93.398, categorized under education and health activities. The funding opportunity number is RFA-CA-20-014, and the original closing date listed in the source information is February 26, 2020, with a creation date of November 19, 2019. While the listing does not provide an award ceiling or expected number of awards in the provided excerpt, the overall program concept is clear: provide targeted, staged support to help standout early postdoctoral researchers move into independent, tenure-track (or equivalent) positions and begin building durable, NCI-aligned research careers, without proposing to lead an independent clinical trial under this particular FOA.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.398.
• This funding opportunity was created on 2019-11-19.
• Applicants must submit their applications by 2020-02-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 20 014

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: